[Bone lesions in multiple myeloma].
The etiology and pathophysiology of bone lesions in multiple myeloma (MM) and the new treatment for bone lesions in MM are mentioned in this report. The osteoclastic activating factors (OAF) include lymphotoxin (TNF-beta), interleukin 1, tumor necrosis factor (TNF-alpha) and several other cytokines. MM patients with multiple bone lesions have low bone density and low serum 1,25-hydroxyvitamin D level. The measurement of bone mineral density using dual-energy X-ray absorptiometry is useful to evaluate the bone lesions in MM. New diphosphates, which strongly inhibit the activity of osteoclasts, are now expected to be effective in the treatment of bone lesions in MM.
Umeda
M
M
First Department of Internal Medicine, Toho University School of Medicine.
Takata
M
M
D001842:Bone and Bones / Q000473:pathology*; D004164:Diphosphonates / Q000627:therapeutic use; D006801:Humans; D009101:Multiple Myeloma / Q000188:drug therapy / Q000473:pathology*
D004164:Diphosphonates